|
|
Autism Research Institute
Autism Research Review International
1987 to 2004, Volumes 1 to 18
D
D8/1 1993, Vol. 07(1) pp. 5
D8/1 1993, Vol. 07(1) pp. 5
d-cycloserine (Seromycin), 2004, Vol. 18(4) pp. 5
d-lactic acidosis, 2002, Vol. 16(3) pp. 2
Dabiri, Louise M., 1994, Vol. 08(3) pp. 1
Dale Carnegie, 1994, Vol. 08(3) pp. 5
Dales, Loring, 2001, Vol. 15(1) pp. 2
Dalmeny, Kath, 2002, Vol. 16(4) pp. 7
Dalton, Paola, 2003, Vol. 17(1) pp. 6
DAN!. See Defeat Autism Now! (DAN!)
Daneshvar, Sabrina, 2003, Vol. 17(1) pp. 5
Daniilidis, J., 2003, Vol. 17(3) pp. 4
Danish MMR/Autism Report, 2002, Vol. 16(3) pp. 1; 2004, Vol. 18(3) pp. 1; 2004, Vol. 27(3) pp. 3.
Danish Psychiatric Central Register, 2004, Vol. 18(3) pp. 1
databases
Davies, Daniel, 2001, Vol. 15(3) pp. 5
Davin, Joan and Peter, 1994, Vol. 08(3) pp. 6
Davis, Gray (CA governor), 2000, Vol. 14(2) pp. 1
Dawbarns law firm, 1996, Vol. 10(4) pp. 1
Dawson, G., 1987, Vol. 01(4) pp. 1
Dawson, Geraldine, 1994, Vol. 08(3) pp. 4; 1999, Vol. 13(1) pp. 1; 2001, Vol. 15(2) pp. 2; 2004, Vol. 18(3) pp. 7.
DBH (dopamine beta-hydroxylase) gene, 2001, Vol. 15(2) pp. 2
de Abajo, Francisco José, 1999, Vol. 13(4) pp. 4
De Fossé, Lies, 2004, Vol. 18(4) pp. 6
De Lorenzo, Robert, 2003, Vol. 17(4) pp. 4
De Souza, Errol, 1989, Vol. 03(1) pp. 4
De Stefano, Frank, 1998, Vol. 12(1) pp. 3
De Troch, C., 2001, Vol. 15(2) pp. 4
DEAL (Dignity through Education and Language Center), 1990, Vol. 04(4) pp. 1; 1991, Vol. 05(1) pp. 1; 1991, Vol. 05(2) pp. 6; 1992, Vol. 06(1) pp. 1; 1992, Vol. 06(3) pp. 1; 1993, Vol. 07(3) pp. 3.
death rates. See mortality rates
Deb, S., 1992, Vol. 06(4) pp. 7
DeCarlo, Regina, 1995, Vol. 09(1) pp. 5
decision making, 1998, Vol. 12(3) pp. 6
deep pressure. See sensory stimulation
Defeat Autism Now! (DAN!)
Arabic information on, 2001, Vol. 15(3) pp. 4
Atlanta (GA) conferences, 2001, Vol. 15(1) pp. 1
"Autism Is Treatable" campaign, 2003, Vol. 17(4) pp. 1; 2004, Vol. 18(2) pp. 1.
Cherry Hill (NJ) conferences, 1998, Vol. 12(4) pp. 1; 1999, Vol. 13(2) pp. 1; 1999, Vol. 13(3) pp. 1; 1999, Vol. 13(4) pp. 1; 2000, Vol. 14(1) pp. 6.
Chicago (IL) conferences, 1996, Vol. 10(1) pp. 1
China conferences, 2003, Vol. 17(1) pp. 2
Dallas (TX) conferences, 1995, Vol. 09(1) pp. 3; 1995, Vol. 09(2) pp. 7; 1996, Vol. 10(2) pp. 1.
Doctor Referral List Questionnaire, 1999, Vol. 13(2) pp. 6
doctors' panels in July, 2001, 2001, Vol. 15(3) pp. 3
effectiveness questionnaire, 2003, Vol. 17(4) pp. 6
history of, 2002, Vol. 16(1) pp. 3; 2002, Vol. 16(2) pp. 3; 2003, Vol. 17(4) pp. 3.
Los Angeles (CA) conferences, 2004, Vol. 18(3) pp. 1
physicians' directory, 1999, Vol. 13(2) pp. 6; 2000, Vol. 14(1) pp. 2; 2001, Vol. 15(4) pp. 2; 2002, Vol. 16(1) pp. 4.
Protocol, 1996, Vol. 10(1) pp. 1; 1996, Vol. 10(2) pp. 1; 1997, Vol. 11(1) pp. 6.
publications, 2000, Vol. 14(3) pp. 4; 2002, Vol. 16(2) pp. 3; 2002, Vol. 00(2) pp. 3.
San Diego (CA) conferences, 1997, Vol. 11(1) pp. 6; 1997, Vol. 11(4) pp. 1; 2000, Vol. 14(2) pp. 2; 2002, Vol. 16(3) pp. 1.
success stories, 2000, Vol. 14(4) pp. 7
Washington, D.C., conferences, 2004, Vol. 18(2) pp. 1
Weldon, Dave (Rep.), Keynote Address, 2004, Vol. 18(2) pp. 3
DeGrauw, Ton J., 2003, Vol. 17(3) pp. 4
DeHart, Judy, 2002, Vol. 16(1) pp. 7
deinstitutionalization movement, 1991, Vol. 05(3) pp. 3; 1991, Vol. 05(4) pp. 6; 1993, Vol. 07(4) pp. 3; 1995, Vol. 09(3) pp. 1; 1995, Vol. 09(4) pp. 6; 1997, Vol. 11(1) pp. 3; 1997, Vol. 11(2) pp. 6; 2000, Vol. 14(2) pp. 6.
Delacato, Carl, 1988, Vol. 02(4) pp. 3; 1990, Vol. 04(4) pp. 3.
DeLong, G. Robert, 1989, Vol. 03(1) pp. 4; 1998, Vol. 12(4) pp. 1; 1999, Vol. 13(2) pp. 2.
Demerol, 1999, Vol. 13(3) pp. 5; 2000, Vol. 14(4) pp. 7.
DeMint, Jim (U.S. Senator), 2004, Vol. 18(4) pp. 3
Dempster, R. J., 2003, Vol. 17(1) pp. 4
dendritic abnormalities, 2001, Vol. 15(2) pp. 1
dental disease, 1998, Vol. 12(1) pp. 7
dental work, 1989, Vol. 03(2) pp. 5; 1996, Vol. 10(4) pp. 5; 1999, Vol. 13(3) pp. 5; 2000, Vol. 14(4) pp. 3.
dentate nucleus, 1999, Vol. 13(3) pp. 7
dentist visit training, 1989, Vol. 03(2) pp. 5; 1996, Vol. 10(4) pp. 5.
Deonna, Thierry, 1992, Vol. 06(1) pp. 6; 1996, Vol. 10(2) pp. 6.
Depakote (divalproex sodium or sodium valproate), 2000, Vol. 14(2) pp. 5; 2001, Vol. 15(3) pp. 5.
Depo Provera, 1999, Vol. 13(2) pp. 7; 2000, Vol. 14(3) pp. 5; 2003, Vol. 17(1) pp. 4.
depression
amantadine hydrochloride (Symmetrel) for, 2001, Vol. 15(4) pp. 2
anxiety in, 1999, Vol. 13(2) pp. 6
and aspartame, 1992, Vol. 06(2) pp. 4
and autism, 1999, Vol. 13(2) pp. 2
and Borna virus, 1996, Vol. 10(3) pp. 5
buspirone for, 1994, Vol. 08(3) pp. 4
eicosopentaenoic acid (EPA) for, 1999, Vol. 13(1) pp. 7
and fluoxetine (Prozac), 1998, Vol. 12(3) pp. 4
forced normalization syndrome, 1999, Vol. 13(3) pp. 4
and Fragile X, 1991, Vol. 05(3) pp. 4
Hypericum for, 2002, Vol. 16(4) pp. 5
from marijuana, 2003, Vol. 17(1) pp. 3
mecamylamine for, 1998, Vol. 12(4) pp. 2
omega-3-fatty acids for, 1999, Vol. 13(1) pp. 7
in retarded people, 1991, Vol. 05(3) pp. 4
risperidone for, 1998, Vol. 12(3) pp. 1
and serotonin levels in parents, 1994, Vol. 08(3) pp. 4
in siblings of autistics, 1991, Vol. 05(3) pp. 6
in Tourette's, 1991, Vol. 05(3) pp. 1; 2002, Vol. 16(4) pp. 7.
and vitamin B6 deficiency, 2004, Vol. 18(4) pp. 4
vitamin C for, 1998, Vol. 12(2) pp. 3
dermatoglyphics, 1990, Vol. 04(2) pp. 4
desipramine, 1992, Vol. 06(2) pp. 7; 1993, Vol. 07(4) pp. 1; 1995, Vol. 09(3) pp. 4; 1995, Vol. 09(4) pp. 4.
destructiveness, 1993, Vol. 07(4) pp. 6; 1996, Vol. 10(2) pp. 2; 1998, Vol. 12(1) pp. 4; 2002, Vol. 16(2) pp. 7; 2003, Vol. 17(1) pp. 3; 2004, Vol. 18(4) pp. 7.
Deth, Richard C., 2004, Vol. 18(1) pp. 1; 2004, Vol. 18(2) pp. 6; 2004, Vol. 18(3) pp. 3; 2004, Vol. 18(4) pp. 6.
detoxification, 2001, Vol. 15(1) pp. 1; 2001, Vol. 15(4) pp. 3; 2003, Vol. 17(2) pp. 4.
D'Eufemia, P., 1996, Vol. 10(1) pp. 6
Deutsch, Stephen, 1987, Vol. 01(4) pp. 4
Developmental Day School, 1991, Vol. 05(2) pp. 6
developmental language disorder, 1987, Vol. 01(4) pp. 6; 2004, Vol. 18(2) pp. 4.
developmental quotient (DQ), 1987, Vol. 01(4) pp. 6
Developmental Services in California Department, 1997, Vol. 11(1) pp. 3
developmentally appropriate activities, 1994, Vol. 08(2) pp. 5
DeWine, Mike (U.S. Senator)
DeWine (U.S. Senator), 2004, Vol. 18(4) pp. 3
dexamethasone suppression test (DST), 1988, Vol. 02(1) pp. 1
dexfenfluramine. See fenfluramine (Pondimin)
DHA (docosahexaenoic acid, an omega-3-fatty acid), 1999, Vol. 13(1) pp. 7; 2000, Vol. 14(4) pp. 6; 2004, Vol. 18(2) pp. 4.
DHPPA metabolites, 1998, Vol. 12(4) pp. 6
diabetes type 2, 1999, Vol. 13(3) pp. 2; 2001, Vol. 15(4) pp. 5; 2002, Vol. 16(2) pp. 6; 2002, Vol. 16(4) pp. 6; 2003, Vol. 17(3) pp. 2; 2004, Vol. 18(2) pp. 2.
diagnosis
abdominal radiographs, 2003, Vol. 17(4) pp. 5
ADHD confused with autism, 1992, Vol. 06(3) pp. 5
in Asperger's, 1992, Vol. 06(1) pp. 4
and autism epidemic, 1995, Vol. 09(3) pp. 3
bedside manner during, 1987, Vol. 01(2) pp. 4
and biological therapy, 2000, Vol. 14(1) pp. 7
CHAT (Checklist for Autism in Toddlers), 1992, Vol. 06(3) pp. 5; 1996, Vol. 10(2) pp. 6.
computer database for, 2001, Vol. 15(1) pp. 3
criteria for autism and PDD, 1991, Vol. 05(2) pp. 2
DAN! Clinical Options Manual, 2000, Vol. 14(3) pp. 4
Diagnostic Standard Manual (DSM), 2000, Vol. 14(1) pp. 7
difficulty of getting, 2000, Vol. 14(3) pp. 4
Fragile X screening, 1993, Vol. 07(2) pp. 4
Human Basophil Degranulation test, 1993, Vol. 07(3) pp. 4
improvement and autism increase, 2003, Vol. 17(1) pp. 1
infancy screening, 2000, Vol. 14(3) pp. 4
of Landau-Kleffner syndrome, 1995, Vol. 09(3) pp. 6
as learning disabled (LD), 1992, Vol. 06(3) pp. 5
Medigenesis website, 2001, Vol. 15(1) pp. 3
multiple complex developmental disorder (MCDD), 1996, Vol. 10(2) pp. 4
organic acid testing, 2000, Vol. 14(1) pp. 7
PDD label, 1993, Vol. 07(2) pp. 3
peptide analysis, 2000, Vol. 14(1) pp. 7
phenylketonuria checkup, 1992, Vol. 06(3) pp. 4
for secretin treatment, 1998, Vol. 12(2) pp. 1; 1998, Vol. 12(3) pp. 3; 1998, Vol. 12(4) pp. 3.
for special-needs services, 1995, Vol. 09(2) pp. 6
SPECT study, 1992, Vol. 06(4) pp. 4
subtypes of autism, 1993, Vol. 07(2) pp. 3; 1999, Vol. 13(2) pp. 2; 2003, Vol. 17(1) pp. 6.
and treatment effectiveness, 1999, Vol. 13(4) pp. 2
tuberous sclerosis screening, 1993, Vol. 07(3) pp. 4
"Diagnosis and Management of Autism" guidelines, 2001, Vol. 15(3) pp. 3
Diagnostic and Statistical Manual of Mental Disorders (DSM), 1991, Vol. 05(2) pp. 2; 1991, Vol. 05(4) pp. 7; 1996, Vol. 10(2) pp. 4; 2000, Vol. 14(1) pp. 7.
Dialyzable Leukocyte Extract, 1989, Vol. 03(4) pp. 1–2
dialyzable lymphocyte extract, 1997, Vol. 11(2) pp. 1
Diamond, Adele, 1995, Vol. 09(2) pp. 4
diarrhea, 1999, Vol. 13(4) pp. 7; 2002, Vol. 16(1) pp. 3; 2002, Vol. 16(3) pp. 2.
diazepam (Valium), 1991, Vol. 05(1) pp. 3; 1993, Vol. 07(4) pp. 5; 1998, Vol. 12(1) pp. 7.
Dickersin, Kay, 2004, Vol. 18(3) pp. 4
Didden, Robert, 1998, Vol. 12(4) pp. 5
Dienel, A., 2002, Vol. 16(4) pp. 5
Dietary Supplement Health and Education Act (DSHEA), 2003, Vol. 17(3) pp. 9
Dietary Supplement Safety Act of 200 1989, Vol. 03(3) pp. 9
diets
Atkins diet, 2004, Vol. 18(1) pp. 2
casein-free (See casein-free diet)
challenge, 1992, Vol. 06(3) pp. 6
eccentric, 1993, Vol. 07(4) pp. 4
elimination, 1989, Vol. 03(2) pp. 6; 1992, Vol. 06(3) pp. 6; 1996, Vol. 10(3) pp. 4.
Feingold diet, 1995, Vol. 09(2) pp. 5; 1995, Vol. 09(4) pp. 6.
funding needed to research autism link to, 1997, Vol. 11(2) pp. 3
gluten-free (See gluten-free diet)
ketogenic, 1988, Vol. 02(2) pp. 4; 1990, Vol. 04(1) pp. 2; 1996, Vol. 10(1) pp. 5; 1997, Vol. 11(1) pp. 5; 2002, Vol. 16(2) pp. 5; 2002, Vol. 16(3) pp. 4; 2004, Vol. 18(1) pp. 2.
low-carbohydrate, 2004, Vol. 18(1) pp. 2
low-phenol, 1995, Vol. 09(4) pp. 6
low-purine, 1990, Vol. 04(1) pp. 2; 1990, Vol. 04(2) pp. 7.
Master's thesis study of, 1997, Vol. 11(2) pp. 6
medium-chain triglyceride, 1988, Vol. 02(2) pp. 4
natural, 1989, Vol. 03(3) pp. 4
non-medium-chain high-fat diet, 1988, Vol. 02(2) pp. 4
oligoantigenic, 1995, Vol. 09(4) pp. 3
for phenylketonuria, 1990, Vol. 04(1) pp. 2
serotoninergic, 1991, Vol. 05(4) pp. 4; 2002, Vol. 16(2) pp. 7.
and vitamin-deficiency diseases, 1995, Vol. 09(3) pp. 3
differential reinforcement of alternative behavior (DRA), 1994, Vol. 08(2) pp. 5; 1999, Vol. 13(4) pp. 5.
differential reinforcement of appropriate behaviors (DRA), 1996, Vol. 10(4) pp. 2
differential reinforcement of incompatible behaviors (DRI), 1995, Vol. 09(1) pp. 5
differential reinforcement of other behaviors (DRO), 1989, Vol. 03(1) pp. 5; 1994, Vol. 08(2) pp. 5; 1994, Vol. 08(4) pp. 5; 1995, Vol. 09(1) pp. 5.
DiGeorge syndrome, 1998, Vol. 12(3) pp. 4
Dignity Through Education and Language. See DEAL
Dilantin. See phenytoin (Dilantin)
Diler, Rasim Somer, 2002, Vol. 16(1) pp. 5; 2003, Vol. 17(3) pp. 7.
Diller, Lawrence, 1997, Vol. 11(4) pp. 1
dimethylglycine. See DMG
Dingell, John (Representative, MI), 1992, Vol. 06(2) pp. 3; 1992, Vol. 06(3) pp. 2; 1994, Vol. 08(3) pp. 7.
dioxin, 1992, Vol. 06(2) pp. 1; 1992, Vol. 06(3) pp. 2; 1997, Vol. 11(4) pp. 2.
dipeptidylpeptidase IV (DPP IV), 2002, Vol. 16(2) pp. 4
diptheria-tetanus-pertussis vaccine. See DPT
directories. See resource guides
disAbilities Forum, 1994, Vol. 08(3) pp. 6
Disability Rights Education and Defense Fund, 1995, Vol. 09(4) pp. 1
"discrete trial" instruction, 2002, Vol. 16(2) pp. 2
diseases. See infections
disruptive behaviors, 1997, Vol. 11(1) pp. 2; 1997, Vol. 11(2) pp. 7.
Dissatisfied Parents Together, 1990, Vol. 04(3) pp. 5
distractibility, 1989, Vol. 03(1) pp. 2; 1998, Vol. 12(2) pp. 2.
diuretics, 2004, Vol. 18(1) pp. 5
divalproex sodium (Depakote), 2000, Vol. 14(2) pp. 5; 2001, Vol. 15(3) pp. 5.
Dixon, R. S., 1996, Vol. 10(2) pp. 5
dizziness, 1992, Vol. 06(2) pp. 4
DMG (dimethylglycine)
and 5-HTP, 1999, Vol. 13(1) pp. 2
for aggression, 1992, Vol. 06(1) pp. 7; 1996, Vol. 10(4) pp. 7; 2001, Vol. 15(4) pp. 3.
for Angelman's syndrome, 2004, Vol. 18(4) pp. 6
for anthrax, 2002, Vol. 16(4) pp. 3
for anxiety, 1990, Vol. 04(4) pp. 7
for attention, 1987, Vol. 01(4) pp. 5; 1993, Vol. 07(2) pp. 6; 1994, Vol. 08(2) pp. 6; 1994, Vol. 08(3) pp. 6.
for behaviors, 1987, Vol. 01(4) pp. 5; 1992, Vol. 06(1) pp. 6; 1992, Vol. 06(2) pp. 6; 1994, Vol. 08(3) pp. 6; 1995, Vol. 09(2) pp. 7; 1997, Vol. 11(3) pp. 6.
cancer link refuted, 1997, Vol. 11(3) pp. 6
for cerebral palsy, 2002, Vol. 16(3) pp. 7
for communication deficits, 1990, Vol. 04(4) pp. 7; 1993, Vol. 07(2) pp. 6.
for concentration, 1990, Vol. 04(4) pp. 7; 1991, Vol. 05(2) pp. 7; 1991, Vol. 05(3) pp. 7; 1993, Vol. 07(2) pp. 6; 1994, Vol. 08(2) pp. 6; 1994, Vol. 08(4) pp. 7.
for conversational skills, 1993, Vol. 07(1) pp. 7
for cooperation, 1992, Vol. 06(3) pp. 6
for coordination, 1992, Vol. 06(2) pp. 6; 1993, Vol. 07(2) pp. 6.
and early intervention, 1998, Vol. 12(1) pp. 2
for echolalia, 1995, Vol. 09(2) pp. 7
for epilepsy, 1993, Vol. 07(4) pp. 5; 1994, Vol. 08(3) pp. 2.
for eye contact, 1993, Vol. 07(3) pp. 6; 1995, Vol. 09(2) pp. 7; 1997, Vol. 11(4) pp. 7; 2001, Vol. 15(3) pp. 6.
and folic acid, 1995, Vol. 09(2) pp. 7; 1996, Vol. 10(3) pp. 7.
for hyperactivity, 1990, Vol. 04(4) pp. 7; 1992, Vol. 06(1) pp. 7.
for insomnia, 1994, Vol. 08(3) pp. 2
for language deficits, 1990, Vol. 04(2) pp. 3; 1990, Vol. 04(4) pp. 7; 1991, Vol. 05(1) pp. 7; 1991, Vol. 05(2) pp. 7; 1991, Vol. 05(3) pp. 7; 1992, Vol. 06(2) pp. 6; 1992, Vol. 06(4) pp. 6; 1993, Vol. 07(2) pp. 6; 1993, Vol. 07(3) pp. 6; 1996, Vol. 10(3) pp. 7; 1997, Vol. 11(1) pp. 6; 1997, Vol. 11(3) pp. 6; 1998, Vol. 12(3) pp. 7.
for mood, 1992, Vol. 06(1) pp. 7
for motor deficits, 1993, Vol. 07(2) pp. 6
and naltrexone, 1992, Vol. 06(2) pp. 2
for obsessive-compulsive-disorder (OCD), 1995, Vol. 09(2) pp. 7; 1996, Vol. 10(3) pp. 7.
for ritualistic behavior, 1992, Vol. 06(1) pp. 7
for seizures, 1990, Vol. 04(2) pp. 3; 1993, Vol. 07(1) pp. 7; 1993, Vol. 07(4) pp. 5; 1994, Vol. 08(3) pp. 2; 1995, Vol. 09(4) pp. 3; 1996, Vol. 10(2) pp. 1.
for self-injury, 1992, Vol. 06(1) pp. 6; 1992, Vol. 06(2) pp. 6.
for social deficits, 1992, Vol. 06(2) pp. 6; 1992, Vol. 06(3) pp. 6; 1993, Vol. 07(3) pp. 6; 1994, Vol. 08(4) pp. 7; 1996, Vol. 10(3) pp. 7; 1997, Vol. 11(4) pp. 7; 1998, Vol. 12(1) pp. 7; 2001, Vol. 15(3) pp. 6.
for speech problems, 1990, Vol. 04(2) pp. 3; 1992, Vol. 06(2) pp. 6; 1992, Vol. 06(3) pp. 6; 1993, Vol. 07(1) pp. 7; 1993, Vol. 07(3) pp. 6; 1996, Vol. 10(2) pp. 1; 1996, Vol. 10(3) pp. 7; 1997, Vol. 11(4) pp. 7; 1998, Vol. 12(1) pp. 7; 1998, Vol. 12(2) pp. 7; 1998, Vol. 12(3) pp. 7; 1999, Vol. 13(2) pp. 7; 2001, Vol. 15(3) pp. 6.
for tantrums, 1993, Vol. 07(4) pp. 6; 1994, Vol. 08(3) pp. 2; 1995, Vol. 09(2) pp. 7.
for toe walking, 1993, Vol. 07(3) pp. 6
for toilet training, 1998, Vol. 12(2) pp. 7
for tooth grinding, 1993, Vol. 07(3) pp. 6
for vomiting, 1995, Vol. 09(2) pp. 7
DMPS (mercury chelator), 2004, Vol. 18(3) pp. 3
DMSA (mercury chelator), 2003, Vol. 17(3) pp. 1; 2004, Vol. 18(3) pp. 3.
"do" versus "don't," 2000, Vol. 14(1) pp. 5
Doctor's Data, 2004, Vol. 18(3) pp. 2
Doctor's Guide to Vitamin B 1992, Vol. 06(G) pp. ,; 1996, Vol. 10(3) pp. 3.
Doerfel, Ken Sue, 1995, Vol. 09(2) pp. 7
dogma and autism research, 1997, Vol. 11(3) pp. 3
dogs, 1989, Vol. 03(4) pp. 2
Dolitsky, Jay N., 2002, Vol. 16(3) pp. 7
dolphins, 1989, Vol. 03(4) pp. 2
Dolphins Plus program, 1989, Vol. 03(4) pp. 2
Dolske, M.C., 1998, Vol. 12(2) pp. 3
Doman, Glenn, 1988, Vol. 02(4) pp. 3
donepezil (Aricept), 2004, Vol. 18(2) pp. 5
Donnellan, Anne, 1988, Vol. 02(3) pp. 6; 1994, Vol. 08(1) pp. 1; 1994, Vol. 08(3) pp. 6.
Donnelly, Julie A., 1995, Vol. 09(2) pp. 5
Donnelly, Shannon L., 2001, Vol. 15(1) pp. 5
Dooley, Robin, 2001, Vol. 15(3) pp. 6
dopamine
and attention deficit disorder (ADD), 1992, Vol. 06(2) pp. 4
and brain abnormalities, 1990, Vol. 04(4) pp. 4
DbetaH enzyme and, 2001, Vol. 15(2) pp. 2
and drugs, 1988, Vol. 02(3) pp. 4; 1994, Vol. 08(4) pp. 1; 1996, Vol. 10(1) pp. 1; 1996, Vol. 10(2) pp. 2; 1996, Vol. 10(3) pp. 2; 1998, Vol. 12(3) pp. 1; 1999, Vol. 13(4) pp. 4; 2000, Vol. 14(2) pp. 4; 2001, Vol. 15(4) pp. 2.
familial patterns studies, 1989, Vol. 03(2) pp. 2
HVA (homovanillic acid) and, 1987, Vol. 01(4) pp. 4
and methylation, 2004, Vol. 18(1) pp. 1
and methylphenidate (Ritalin), 2004, Vol. 18(4) pp. 5
and neuroleptic malignant syndrome, 1994, Vol. 08(1) pp. 1; 1996, Vol. 10(3) pp. 2.
nicotine for Tourette's, 1998, Vol. 12(2) pp. 7
and PPI (prepulse inhibition), 2003, Vol. 17(2) pp. 2
R-THBP and, 1997, Vol. 11(4) pp. 4
in Rett Syndrome, 1987, Vol. 01(2) pp. 6; 1988, Vol. 02(1) pp. 4; 1989, Vol. 03(2) pp. 4; 1990, Vol. 04(4) pp. 4; 1994, Vol. 08(4) pp. 4.
and self-injury, 1996, Vol. 10(1) pp. 1
and serotonin, 1987, Vol. 01(4) pp. 4; 2003, Vol. 17(3) pp. 7.
and serum prolactin, 1999, Vol. 13(4) pp. 4
and stereotypies, 1988, Vol. 02(2) pp. 2; 1988, Vol. 02(3) pp. 4.
and supplements, 1988, Vol. 02(4) pp. 2; 1992, Vol. 06(1) pp. 4; 1995, Vol. 09(1) pp. 4; 1998, Vol. 12(4) pp. 6; 2001, Vol. 15(4) pp. 6.
and zinc, 2004, Vol. 18(2) pp. 5
dopamine beta-hydroxylase (DBH) gene, 2001, Vol. 15(2) pp. 2
Dorris, Liam, 2004, Vol. 18(1) pp. 5
dosage. See also supplements, individual drugs
for DMG, 1997, Vol. 11(4) pp. 3
and intake compared, 1990, Vol. 04(2) pp. 3
lowering through exercise, 1989, Vol. 03(1) pp. 1
for magnesium, 1997, Vol. 11(4) pp. 3
and neuroleptic malignant syndrome, 1994, Vol. 08(1) pp. 1
for risperidone, 1997, Vol. 11(3) pp. 2
for secretin, 1998, Vol. 12(4) pp. 3
for vitamin B6, 1995, Vol. 09(2) pp. 7; 1997, Vol. 11(4) pp. 3; 1998, Vol. 12(2) pp. 3.
for vitamin C, 1997, Vol. 11(4) pp. 3
double-blind studies, 1993, Vol. 07(4) pp. 4; 1999, Vol. 13(3) pp. 3.
Douglas, Gordon, 2004, Vol. 18(4) pp. 2
Douglass Developmental Disabilities Center at Rutgers University, 1991, Vol. 05(4) pp. 5
Down syndrome
downstream effect, 1988, Vol. 02(2) pp. 7; 1993, Vol. 07(3) pp. 4; 1994, Vol. 08(2) pp. 7; 1997, Vol. 11(3) pp. 1.
DPP IV (dipeptidylpeptidase IV), 2002, Vol. 16(2) pp. 4
DPT: Shot in the Dark (Coulter and Fisher), 1998, Vol. 12(1) pp. 3
DPT (diptheria pertussis tetanus) vaccines. See also DTP
apnea from, 1999, Vol. 13(3) pp. 1
and autism onset, 1998, Vol. 12(1) pp. 3; 2000, Vol. 14(1) pp. 3; 2001, Vol. 15(3) pp. 3.
and encephalitis, 1995, Vol. 09(1) pp. 1; 1996, Vol. 10(1) pp. 3.
Form E-3 questions, 2000, Vol. 14(4) pp. 3
and immune system, 1996, Vol. 10(1) pp. 3
DQ, 1987, Vol. 01(4) pp. 6
Dr. LeoKannerhuis (Netherlands community), 1990, Vol. 04(3) pp. 3
DRA (differential reinforcement of alternative behavior), 1994, Vol. 08(2) pp. 5; 1999, Vol. 13(4) pp. 5.
DRA (differential reinforcement of appropriate behaviors), 1996, Vol. 10(4) pp. 2
Drash, Phillip W., 1989, Vol. 03(4) pp. 6
Drawbridge, Penny, 1988, Vol. 02(3) pp. 6
Dreyfus, Pierre, 1987, Vol. 01(4) pp. 3; 2000, Vol. 14(3) pp. 3.
DRI (differential reinforcement of incompatible behaviors), 1995, Vol. 09(1) pp. 5
drinking behaviors, 1997, Vol. 11(1) pp. 2; 1999, Vol. 13(2) pp. 4.
DRO (differential reinforcement of other behaviors), 1989, Vol. 03(1) pp. 5; 1994, Vol. 08(2) pp. 5; 1994, Vol. 08(4) pp. 5; 1995, Vol. 09(1) pp. 5.
drug abuse, 1991, Vol. 05(3) pp. 1
drug companies, 2003, Vol. 17(3) pp. 3; 2003, Vol. 17(4) pp. 7; 2004, Vol. 18(4) pp. 2.
drug interactions
with carbamazepine, 1996, Vol. 10(3) pp. 4
clomipramine and rages, 1993, Vol. 07(3) pp. 1; 1993, Vol. 07(4) pp. 1; 1996, Vol. 10(3) pp. 6.
clonidine, 1996, Vol. 10(1) pp. 7
computer websites on, 1996, Vol. 10(3) pp. 4
contraceptives, 1996, Vol. 10(3) pp. 4
dosing, 1997, Vol. 11(3) pp. 2
with Dyazide, 1996, Vol. 10(3) pp. 4
with grapefruit juice, 1997, Vol. 11(3) pp. 6
with Haldol, 1988, Vol. 02(3) pp. 4
with Hismanal, 1996, Vol. 10(3) pp. 4
methylphenidate (Ritalin), 1996, Vol. 10(1) pp. 7
with Nizoral, 1996, Vol. 10(3) pp. 4
with Pepcid, 1997, Vol. 11(3) pp. 4
from pharmacy errors, 1996, Vol. 10(3) pp. 4
with phenytoin, 1996, Vol. 10(2) pp. 2
with Rimactane, 1996, Vol. 10(3) pp. 4
with risperidone, 1996, Vol. 10(2) pp. 2; 1997, Vol. 11(3) pp. 2.
tardive dyskinesia and autism stereotypies compared, 1989, Vol. 03(4) pp. 5
with Vasotec, 1996, Vol. 10(3) pp. 4
with vitamin C, 1988, Vol. 02(3) pp. 4
drug trials registry, 2004, Vol. 18(3) pp. 4; 2004, Vol. 18(4) pp. 4.
drugs
acyclovir, 1997, Vol. 11(2) pp. 2
African Americans' drug reactions, 2000, Vol. 14(1) pp. 4
Alzheimer's drugs, 2004, Vol. 18(2) pp. 5
amantadine hydrochloride (Symmetrel), 2001, Vol. 15(4) pp. 2
anti-convulsants (See anti-convulsants)
antibiotics for middle ear infections, 1992, Vol. 06(4) pp. 4; 1994, Vol. 08(4) pp. 1; 1995, Vol. 09(3) pp. 3; 1997, Vol. 11(1) pp. 7; 1998, Vol. 12(4) pp. 1; 2000, Vol. 14(3) pp. 2; 2001, Vol. 15(4) pp. 7.
antidepressants and psychiatric symptoms, 2003, Vol. 17(2) pp. 4; 2004, Vol. 18(3) pp. 2.
antihistamines, 1997, Vol. 11(3) pp. 6
antipsychotics, 1999, Vol. 13(3) pp. 2; 2000, Vol. 14(4) pp. 4; 2001, Vol. 15(4) pp. 5; 2002, Vol. 16(2) pp. 6; 2002, Vol. 16(4) pp. 6; 2003, Vol. 17(3) pp. 2; 2004, Vol. 18(2) pp. 2.
aripiprazole (Abilify), 2003, Vol. 17(3) pp. 2; 2004, Vol. 18(2) pp. 2.
atropine, 2000, Vol. 14(4) pp. 7
Autism Summit's prejudice towards, 2003, Vol. 17(4) pp. 1
aversives as alternatives to, 1988, Vol. 02(3) pp. 8; 1989, Vol. 03(4) pp. 1.
AZT, 1995, Vol. 09(2) pp. 5
Bechanechol, 2000, Vol. 14(1) pp. 6
Benadryl, 1993, Vol. 07(3) pp. 5; 2003, Vol. 17(1) pp. 4.
beta blockers, 1987, Vol. 01(3) pp. 4
black-box warning for antidepressants, 2004, Vol. 18(3) pp. 2
books about, 1997, Vol. 11(2) pp. 7
bromacriptine, 1987, Vol. 01(2) pp. 6; 1988, Vol. 02(3) pp. 4; 1990, Vol. 04(4) pp. 4; 1991, Vol. 05(1) pp. 7; 1996, Vol. 10(1) pp. 2.
buproprion (Wellbutrin), 2004, Vol. 18(3) pp. 6
buspirone, 1990, Vol. 04(3) pp. 7; 1991, Vol. 05(4) pp. 4; 1992, Vol. 06(2) pp. 2; 1994, Vol. 08(3) pp. 4; 1996, Vol. 10(1) pp. 4; 2002, Vol. 16(2) pp. 7.
cefaclor for middle ear infections, 1992, Vol. 06(4) pp. 4
cerebrolysin, 2003, Vol. 17(3) pp. 5
and children, 2004, Vol. 18(2) pp. 4
chloral hydrate, 1991, Vol. 05(1) pp. 4
chlorpromazine, 1989, Vol. 03(3) pp. 4; 2000, Vol. 14(4) pp. 4.
citalopram (Celexa), 2004, Vol. 18(1) pp. 9; 2004, Vol. 18(3) pp. 6.
clomipramine, 1993, Vol. 07(S) pp.
clonidine (Catapres), 1992, Vol. 06(3) pp. 2; 1995, Vol. 09(4) pp. 4; 1996, Vol. 10(1) pp. 7; 2000, Vol. 14(1) pp. 4.
clozapine (Clozaril) (See clozapine)
corticosteroids, 1991, Vol. 05(2) pp. 1; 1995, Vol. 09(2) pp. 1; 1995, Vol. 09(3) pp. 1; 1995, Vol. 09(4) pp. 3; 2000, Vol. 14(3) pp. 5.
d-cycloserine (Seromycin), 2004, Vol. 18(4) pp. 5
and dental disease, 1998, Vol. 12(1) pp. 7
desipramine, 1992, Vol. 06(2) pp. 7; 1993, Vol. 07(4) pp. 1; 1995, Vol. 09(3) pp. 4; 1995, Vol. 09(4) pp. 4.
diazepam, 1993, Vol. 07(4) pp. 5
divalproex sodium (Depakote), 2000, Vol. 14(2) pp. 5; 2001, Vol. 15(3) pp. 5.
donepezil (Aricept), 2004, Vol. 18(2) pp. 5
dopamine-receptor blocking drugs, 1996, Vol. 10(3) pp. 2
escitalopram (Lexapro), 2004, Vol. 18(1) pp. 9
ethnicity and reaction to, 2000, Vol. 14(1) pp. 4
and exercise compared, 1988, Vol. 02(4) pp. 3
fatalities from, 1994, Vol. 08(1) pp. 1; 1996, Vol. 10(1) pp. 7.
felbamate, 1993, Vol. 07(4) pp. 5; 1994, Vol. 08(2) pp. 7; 1994, Vol. 08(3) pp. 2.
fenfluramine (See fenfluramine)
fluoxetine (Prozac) (See fluoxetine)
fluvoxamine (Luvox) (See fluvoxamine)
gabapentin for epilepsy, 1993, Vol. 07(4) pp. 5
galantamine (Reminyl), 2002, Vol. 16(4) pp. 5
guides to, 1997, Vol. 11(2) pp. 7
haloperidol (Haldol), 1990, Vol. 04(H) pp.
imipramine, 1987, Vol. 01(1) pp. 4; 1991, Vol. 05(1) pp. 3; 1991, Vol. 05(2) pp. 4.
ketamine, 1999, Vol. 13(3) pp. 5; 2000, Vol. 14(4) pp. 7.
lamotrigine, 1993, Vol. 07(4) pp. 5; 1998, Vol. 12(2) pp. 5.
Levetiracetam (Keppra), 2002, Vol. 16(4) pp. 4
lithium, 1988, Vol. 02(1) pp. 1; 1989, Vol. 03(3) pp. 4; 1995, Vol. 09(4) pp. 1; 2002, Vol. 16(1) pp. 2; 2002, Vol. 16(3) pp. 4; 2003, Vol. 17(4) pp. 5.
marijuana, 1998, Vol. 12(2) pp. 7; 2002, Vol. 16(2) pp. 7; 2002, Vol. 16(3) pp. 7; 2003, Vol. 17(1) pp. 3; 2003, Vol. 17(2) pp. 7; 2003, Vol. 17(3) pp. 6; 2003, Vol. 17(4) pp. 4.
Marinol, 2003, Vol. 17(1) pp. 3; 2003, Vol. 17(2) pp. 6; 2003, Vol. 17(3) pp. 6.
and meditation compared for aggression, 2003, Vol. 17(3) pp. 7
Mellaril, 1991, Vol. 05(4) pp. 4; 2000, Vol. 14(4) pp. 4; 2003, Vol. 17(4) pp. 5.
meripidine (Demerol), 1999, Vol. 13(3) pp. 5; 2000, Vol. 14(4) pp. 7.
methylphenidate (Ritalin), 1991, Vol. 05(4) pp. 4; 1993, Vol. 07(4) pp. 4; 1995, Vol. 09(1) pp. 7; 1996, Vol. 10(1) pp. 7; 2000, Vol. 14(1) pp. 2.
midazolam (Versed), 1999, Vol. 13(3) pp. 5; 2000, Vol. 14(4) pp. 7.
mirtrazapine (Remeron), 2004, Vol. 18(1) pp. 9; 2004, Vol. 18(3) pp. 6.
nadolol, 1990, Vol. 04(3) pp. 7
naltrexone (See naltrexone)
nefazodone (Serzone), 2004, Vol. 18(1) pp. 9; 2004, Vol. 18(3) pp. 6.
nicotine, 1998, Vol. 12(2) pp. 1; 1998, Vol. 12(4) pp. 2.
Norplant, 1995, Vol. 09(4) pp. 4; 1996, Vol. 10(2) pp. 4; 2003, Vol. 17(1) pp. 4.
nortriptyline, 1995, Vol. 09(3) pp. 4
and nutrition, 1993, Vol. 07(2) pp. 2
olanzapine (Zyprexa), 1999, Vol. 13(3) pp. 2; 2001, Vol. 15(1) pp. 4; 2002, Vol. 16(2) pp. 6; 2002, Vol. 16(4) pp. 6; 2003, Vol. 17(3) pp. 2; 2004, Vol. 18(2) pp. 2.
oppositional model of tolerance, 2003, Vol. 17(2) pp. 4
oxytocin, 1992, Vol. 06(3) pp. 4; 1993, Vol. 07(4) pp. 4; 1996, Vol. 10(3) pp. 2; 1997, Vol. 11(4) pp. 7; 2001, Vol. 15(1) pp. 4; 2002, Vol. 16(4) pp. 5.
paroxetine (Paxil), 2002, Vol. 16(4) pp. 6; 2003, Vol. 17(3) pp. 2; 2004, Vol. 18(1) pp. 9; 2004, Vol. 18(2) pp. 4; 2004, Vol. 18(3) pp. 2.
pediazole, 1992, Vol. 06(4) pp. 4
pemoline (Cylert), 2000, Vol. 14(1) pp. 2
pentoxifylline, 1997, Vol. 11(1) pp. 1; 1997, Vol. 11(2) pp. 7.
Pepcid, 1995, Vol. 09(1) pp. 5; 1997, Vol. 11(2) pp. 7; 1997, Vol. 11(3) pp. 4; 1999, Vol. 13(1) pp. 7; 1999, Vol. 13(2) pp. 2; 2001, Vol. 15(2) pp. 6.
phenobarbital, 1990, Vol. 04(1) pp. 6; 1991, Vol. 05(1) pp. 3; 1993, Vol. 07(4) pp. 5; 2004, Vol. 18(3) pp. 4.
phenytoin (Dilantin), 1993, Vol. 07(4) pp. 5; 1996, Vol. 10(2) pp. 2; 2001, Vol. 15(4) pp. 4; 2002, Vol. 16(2) pp. 5; 2004, Vol. 18(3) pp. 4.
pimozide (ORAP), 2000, Vol. 14(1) pp. 4
propofol, 1999, Vol. 13(3) pp. 5
propranolol, 1990, Vol. 04(3) pp. 7; 1999, Vol. 13(3) pp. 5.
on psychotropics in schools, 2003, Vol. 17(2) pp. 5
quetiapine fumarate (Seroquel), 1999, Vol. 13(4) pp. 4; 2002, Vol. 16(4) pp. 6; 2003, Vol. 17(3) pp. 2; 2004, Vol. 18(2) pp. 2.
and rabbit syndrome, 1995, Vol. 09(2) pp. 4
registry of clinical drug trials, 2004, Vol. 18(3) pp. 4
and respiratory dyskinesia, 1995, Vol. 09(2) pp. 4
for retarded individuals, 1994, Vol. 08(1) pp. 1
risperidone (See risperidone)
rivastigmine tartrate (Excelon), 2004, Vol. 18(2) pp. 5
sertraline (Zoloft), 1996, Vol. 10(4) pp. 2; 1998, Vol. 12(2) pp. 4; 2004, Vol. 18(1) pp. 9; 2004, Vol. 18(3) pp. 6.
for sound sensitivity, 1991, Vol. 05(1) pp. 3
Spirolactone, 1998, Vol. 12(4) pp. 7
SRIs, 1998, Vol. 12(2) pp. 6
SSRIs (selective serotonin reuptake inhibitors), 1996, Vol. 10(4) pp. 2; 1997, Vol. 11(1) pp. 4; 1997, Vol. 11(2) pp. 4; 1998, Vol. 12(1) pp. 7; 1998, Vol. 12(2) pp. 6; 1999, Vol. 13(4) pp. 4; 2004, Vol. 18(1) pp. 4.
sulpiride, 1989, Vol. 03(2) pp. 4
and supplements compared, 1999, Vol. 13(4) pp. 3; 2000, Vol. 14(4) pp. 4.
and tardive dyskinesia (TD) (See tardive dyskinesia (TD))
terbutaline, 2004, Vol. 18(3) pp. 6; 2004, Vol. 18(4) pp. 7.
THC (tetrahydocannabinol), 2003, Vol. 17(1) pp. 3; 2003, Vol. 17(4) pp. 4.
Trazadone, 1992, Vol. 06(1) pp. 5; 2002, Vol. 16(2) pp. 7.
vagus nerve stimulator for less dependency on, 2001, Vol. 15(2) pp. 7
valproic acid, 1994, Vol. 08(2) pp. 7; 1998, Vol. 12(1) pp. 5; 2000, Vol. 14(3) pp. 5; 2002, Vol. 16(2) pp. 5.
vancomycin, 2000, Vol. 14(3) pp. 2
venlafaxine (Effexor), 2000, Vol. 14(2) pp. 4; 2003, Vol. 17(3) pp. 2; 2004, Vol. 18(1) pp. 9; 2004, Vol. 18(3) pp. 6.
ziprasidone (Geodon), 2003, Vol. 17(3) pp. 2; 2004, Vol. 18(1) pp. 6; 2004, Vol. 18(2) pp. 2.
DST (dexamethazone suppression test), 1988, Vol. 02(1) pp. 1
DTaP (diptheria-tetanus-acellular-pertussis) vaccines, 2003, Vol. 17(1) pp. 2; 2003, Vol. 17(2) pp. 2; 2003, Vol. 17(4) pp. 2.
DTP (diptheria-tetanus-pertussis) vaccines. See also DPT
DTwcP (diptheria-pertussis-whole-cell-pertussis) vaccines, 2003, Vol. 17(1) pp. 2; 2003, Vol. 17(2) pp. 2.
Dubovsky, Steven L., 1996, Vol. 10(4) pp. 7; 1997, Vol. 11(1) pp. 4.
Duchame, Joseph M., 1994, Vol. 08(1) pp. 5
Duchan, Judith, 1993, Vol. 07(2) pp. 7
Dufrense, Derrick, 1989, Vol. 03(2) pp. 7
Duker, Pieter C., 1994, Vol. 08(3) pp. 5; 1996, Vol. 10(4) pp. 1.
Dunlap, Glen, 1988, Vol. 02(1) pp. 5; 1988, Vol. 02(2) pp. 2; 1994, Vol. 08(4) pp. 5.
Dunn, Kari L., 1990, Vol. 04(4) pp. 7
duodenitis, 1999, Vol. 13(4) pp. 7
Duperon, Donald, 1991, Vol. 05(3) pp. 5
Durand, V. Mark
functional communication study, 1992, Vol. 06(1) pp. 5; 1994, Vol. 08(1) pp. 2.
group homes and institutions compared, 1995, Vol. 09(3) pp. 1; 1995, Vol. 09(4) pp. 6.
mood music for tantrums and self-injury, 1998, Vol. 12(1) pp. 5
on non-aversives, 1987, Vol. 01(4) pp. 5; 1988, Vol. 02(3) pp. 2.
on positive reinforcers, 1989, Vol. 03(4) pp. 6
Durbin, Richard (IL Senator), 2003, Vol. 17(3) pp. 9
Dursun, S. M., 1998, Vol. 12(2) pp. 1; 1998, Vol. 12(4) pp. 6.
Dwyer, Judith T., 1989, Vol. 03(1) pp. 4
Dyazide, 1996, Vol. 10(3) pp. 4
Dyer, Kathleen, 1989, Vol. 03(2) pp. 5
dyskinesia, 1989, Vol. 03(4) pp. 5; 1996, Vol. 10(4) pp. 7; 2002, Vol. 16(1) pp. 5. See also tardive dyskinesia
dyslexia, 2000, Vol. 14(4) pp. 6
dystonia, 1997, Vol. 11(1) pp. 4
Dzingalasevic, Goran, 1988, Vol. 02(2) pp. 7; 1989, Vol. 03(2) pp. 5.
© copyright 2005, 2006 Autism Research Institute
|
|
